All News

Explore the latest advancements in chronic lymphocytic leukemia treatment, focusing on BTK and BCL2 inhibitors, monoclonal antibodies, and patient management strategies.

Experts emphasize the need to understand patient journeys, navigate complex value chains, and strategically match the right patients with groundbreaking therapies.

Experts share operational challenges and patient care implications of the Inflation Reduction Act's (IRA) drug pricing reforms.

A novel orally bioavailable RIPTAC therapeutic targeting the p53-Y220C mutation demonstrates selective cancer cell killing by inducing proximity between mutant p53 and an essential protein, offering a promising new strategy for treating historically untreatable tumors.

Pharmacists discuss how drug design impacts drug efficacy and indications for HER2-low and -ultra-low breast cancer.

Hyperglycemia is a common and significant adverse effect of PI3K and AKT inhibitors in hormone receptor-positive (HR+) breast cancer.

Rising costs of these therapies challenge affordability and access.

FDA approves Zevaskyn, the first gene therapy for RDEB, offering hope for effective wound healing and pain relief in patients.

A 15-mg dose with a corticosteroid taper regimen was superior to placebo in sustained remission from week 12 to 52.

Alongside regular monitoring and pharmacotherapy, key lifestyle changes can help manage and prevent high blood pressure.

Study shows a significant decline in breast cancer mortality across multiple subtypes.

Experts at Asembia’s AXS25 Summit discussed the economics of specialty pharmacy for rare diseases, addressing high treatment costs and strategies for balancing innovation.

Integrating community pharmacists into specialty pharmacy care can enhance patient access, address physician shortages, and expand pharmacists' roles in delivering high-quality clinical services, according to experts at Asembia’s AXS25 Summit.

Acneiform rash is a common adverse effect of EGFR-targeting therapies.

No matter what role you are in as a pharmacist, no matter where you work or how long you have been practicing, understand that making a difference in the life of a patient matters.

Dostarlimab in the neoadjuvant setting yielded a 100% clinical complete response in patients with rectal cancer.

A phase 2 trial showed that using ctDNA to guide adjuvant pembrolizumab therapy after surgery effectively cleared minimal residual disease and reduced recurrence in patients with resected mismatch repair-deficient (dMMR) solid tumors.

The study found that 4 weeks was the ideal time point to test for cTDNA.

Ochsner Children’s Hospital, in partnership with ISMP, has launched a fellowship to advance pediatric medication safety through hands-on training in key competencies, national safety strategies, interdisciplinary collaboration, and innovative tools such as AI and data dashboards.

Patients Should Also Have a Diet Rich in Fruits, Oily Fish, and Cereals

Certain antibiotics may have a more significant impact on CAR T-cell efficacy and toxicity.

AI may help to accurately classify pediatric sarcoma subtypes using digitized pathology images, potentially improving diagnosis and treatment accessibility across diverse health care settings.

Pharmacists play a crucial role in advancing biosimilar adoption through targeted education and by addressing misconceptions about safety and efficacy.

Interim results from the phase 1 SENTI-202-101 trial show that SENTI-202, a logic-gated, off-the-shelf chimeric antigen receptor natural killer (CAR NK) cell therapy, achieved complete remission in 4 patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).

Pretrained foundation machine learning models significantly improved the accuracy of diagnosing non-melanoma skin cancer from digital pathology images and may offer a practical, resource-efficient solution for cancer diagnosis in underserved settings.

Zoldonrasib, a novel oral KRAS G12D-selective inhibitor, demonstrated promising safety and early antitumor activity in patients with previously treated non–small cell lung cancer (NSCLC), offering a potential new targeted therapy for this underserved population.